p75NTR

Abstract selected for oral presentation at 8am EST on 19 NovemberSANDWICH, United Kingdom, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, today announces it will be presenting the results from its Phase II trial of LEVI-04 in an oral presentation at the American College of Rheumatology's annual meeting, ACR Convergence 2024, being held from 14 November to 19 November, 2024 in Washington, DC. LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) that provides analgesia via inhibition of NT-3 activity and returns neurotrophin homeostasis by supplementing the endogenous p75NTR binding protein to scavenge excess neurotrophins present in osteoarthritis. The data being presented at the conference are from Levicept's multiple-arm, multicentre, randomized, double-blind, placebo-controlled, Phase II study which enrolled 518 participants with pain and disability due to osteoarthritis of the knee (ClinicalTrials.gov ID: NCT05618782). Professor Philip Conaghan MD, Director NIHR Leeds Biomedical Research Centre, Principal Investigator, who will present the data, said, “We look forward to presenting more details of what were truly exceptional results from this robust and well-designed study. Safe and effective pain management is of critical importance in osteoarthritis with existing treatments limited by adverse effects, addiction liabilities and poor efficacy and we believe LEVI-04 has the potential to offer a vital new treatment option to millions of patients in need.” Presentation details: Title: LEVI-04, a novel neurotrophin-3 inhibitor, substantially improves pain and function without deleterious effects on joint structure in people with knee osteoarthritis: a randomised controlled Phase II trial. Authors: Conaghan, Philip G; Guermazi, Ali; Katz, Nathaniel; Bihlet, Asger R; Rom, Dror; Perkins, C Michael; Hughes, Bernadette, Herholdt, Claire; Bombelka, Iwona; Westbrook, Simon. Abstract Number: L15 Date and Time: Tuesday, 19 November, 2024, 08:00 EST Levicept Eliot Forster, CEO – eliot@levicept.com Media Enquiries Charles Consultants Sue Charles - Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner - Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Levicept – www.levicept.com Levicept Ltd is a UK-based biotechnology company developing the first in a new class of novel, safe and efficacious biological therapies, LEVI-04 [p75NTR-Fc], for the treatment of osteoarthritis and chronic pain. LEVI-04 inhibits NT-3, one of the neurotrophin family of proteins. LEVI-04 has completed a Phase II clinical trial in more than 500 patients with osteoarthritis. It is estimated that the market opportunity for drugs that treat osteoarthritis is worth in excess of $10 billion. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. Follow us on LinkedIn - https://www.linkedin.com/company/levicept-ltd

Combination Therapy Approach Stemming from ADDF Advisory Board Expected to Shape the Next Generation of Alzheimer's Treatments Novel Therapies Guided by the Biology of Aging Take Center Stage at CTAD, Reflecting the Evolution of the Drug Pipeline NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will be leading a roundtable, "Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments," at the 2024 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 29th through November 1st in Madrid, Spain. Moderated by Jeffrey Cummings, MD, ScD, Joy Chambers-Grundy Professor of Brain Science at the School of Integrated Health Sciences at University of Nevada, Las Vegas (UNLV), the panel will feature Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF alongside leading experts from industry, academia, and clinical research. The panel takes place on Wednesday, October 30th at 1:45pm CET and will expand upon the recommendations of an expert advisory board—convened by the ADDF at the beginning of the year—that recently provided key considerations on how best to approach and accelerate combination therapy trials for Alzheimer's. "Decades of research has brought us to a pivotal point in the field where the learnings and advances we've gained can now be applied to a robust and diverse pipeline, create a promising path forward for combination therapy trials. These more complex trials—that will look to combine anti-amyloids with novel therapies—are critical to developing the next generation of treatments that will enable precision medicine approach," notes Dr. Fillit. "The patients and families living with this debilitating disease cannot afford for us to take our foot off the gas, we must maintain the momentum toward developing a much-needed personalized and multi-pronged solution." Dr. Fillit will also chair a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," on Thursday, October 31st at 11:25am CET. This session will highlight several promising therapeutic programs exploring the underlying aging pathologies contributing to the onset of Alzheimer's, which are indicative of the larger drug pipeline where nearly 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau. CTAD will feature several key sessions from ADDF-funded investigators, whose work in drug development and biomarkers is shaping and leading the field towards the holy grail of Alzheimer's treatments—combination therapy and precision medicine, similar to cancer care. Dr. Fillit will participate in several sessions around timely developments: Roundtable: "Forging the Path Forward: Capitalizing on Recent Alzheimer's Momentum through Strategic Investments in Novel Therapeutics" on Wednesday, October 30th at 1:45pm CET Moderator: Jeffrey Cummings, MD, ScD (UNLV) Panelists: Howard Fillit, MD (ADDF), Michael Gold, MD (Compass Pathways), Suzanne Hendrix, PhD (Pentara), Mark Mintun, MD, (Eli Lilly), and Jin Zhou, PhD (Eisai) Session: "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease" on Thursday, October 31st at 11:25 am CET Chair: Howard Fillit, MD Additional sessions from ADDF-funded investigators include: Oral Communication: "Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer's Disease" with Cognition Therapeutics on Tuesday, October 29th at 5:55pm CET Late Breaker: "Safety and Preliminary Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer's Disease – Interim Data from a Phase 1/2, Open-Label, 52-Week, Multicenter Study" with Lexeo on Wednesday, October 30th at 10:50am CET Late Breaker: "Plasma p-tau217 and related CSF proteomic markers of pathological progression are slowed by p75NTR modulation: A Phase 2a trial of LM11A31 in Alzheimer's disease" with PharmatophiX on Thursday, October 31st at 8:30am CET To view the full program for the 2024 CTAD conference, visit the conference webpage. About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

All primary and secondary efficacy endpoints met – significant analgesia across all measures for all doses Well tolerated with no increase in incidence of rapid joint deterioration compared to placebo First in class novel biologic under development as non-addictive pain treatment Aug. 06, 2024 -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis and other pain indications, today announces positive results from its Phase II trial of LEVI-04 a novel and first in class neurotrophin-3 (NT-3) inhibitor, showing that LEVI-04 was highly effective and well tolerated. The multiple arm, multicentre, randomised, double-blind, placebo-controlled, Phase II study enrolled more than 510 participants with pain and disability due to osteoarthritis of the knee (ClinicalTrials.gov ID: NCT05618782). The trial was conducted at sites across Europe and in Hong Kong, led by Professor Philip Conaghan MD from the University of Leeds and Leeds Teaching Hospitals NHS Trust, UK. LEVI-04 demonstrated significant differences to placebo at Week 17 for all primary and secondary endpoints for all doses evaluated: The primary endpoint was WOMACi pain assessment (change from baseline at Week 17). The mean reduction in WOMAC pain score from baseline was greater than 50% for all three doses of LEVI-04 and all statistically different to placebo. Secondary endpoints were WOMAC subscales of function and joint stiffness, patient global assessment and daily pain scores and all statistically different to placebo. Standard safety monitoring plus peripheral nervous system assessments showed LEVI-04 to be well tolerated. There was no increase in incidence of rapidly progressive osteoarthritis (RPOA) as measured via detailed, closely examined, radiographic analysis. Levicept intends to submit full results for publication in a peer-reviewed journal. Professor Philip Conaghan MD, Director NIHR Leeds Biomedical Research Centre and Principal Investigator said, “These results are truly exceptional and clinically meaningful in their extent. Safe and effective pain management is of critical importance in arthritis with existing treatments limited by adverse effects, addiction liabilities and poor efficacy. In this trial, LEVI-04 has demonstrated the potential to safely harness the analgesic properties of neurotrophin-3 inhibition and offer a vital new treatment option to millions of patients in huge need. If Phase III trials replicate these results, LEVI-04 would represent a major break-through for osteoarthritis treatment, and with substantial potential in other pain indications.” Globally, 595 million people had osteoarthritis (OA) in 2020, affecting 7.6% of the population and making it the most common form of arthritisii. It is estimated that the market opportunity for drugs that treat OA is worth in excess of $10 billioniii. Simon Westbrook, founder and CSO of Levicept, “The discovery of LEVI-04 harnessed the power of evolution to design a molecule that supplements the endogenous NT regulator, soluble p75NTR. LEVI-04 provides analgesia via inhibition of neurotrophin-3, while avoiding the use-limiting side effects of anti-NGF antibodies, including rapidly progressive of osteoarthritis. LEVI-04 retains the important trophic effects of the neurotrophins, including joint re-modelling. We want to thank all the clinicians and trial participants and hope that the results bring the prospect of a new treatment for them and many others.” Kevin Johnson, Chairman of Levicept and Partner at founding investor Medicxi said, “The results from this robust and large-scale Phase II fully validate the belief of Levicept’s founders and investors that LEVI-04 could be a genuine breakthrough in the treatment of osteoarthritis. They also leave Levicept exceptionally well-positioned to consider the next strategic options to advance LEVI-04’s development.” LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) that provides analgesia via inhibition of NT-3 activity and returns neurotrophin homeostasis by supplementing the endogenous p75NTR binding protein to scavenge excess neurotrophins present in chronic pain states. Levicept Ltd is a UK-based biotechnology company developing the first in a new class of novel, safe and efficacious biological therapies, LEVI-04 [p75NTR-Fc], for the treatment of osteoarthritis and chronic pain. LEVI-04 inhibits NT-3, one of the neurotrophin family of proteins. LEVI-04 has completed a Phase II clinical trial in more than 500 patients with osteoarthritis. It is estimated that the market opportunity for drugs that treat osteoarthritis is worth in excess of $10 billion. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. i The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain scale – a recognised standard pain scale ii https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00163-7/fulltext iii Global Neurotrophins Market- Analysis, Size, Forecast 2033 (futuremarketinsights.com) The content above comes from the network. if any infringement, please contact us to modify.